(C) 2022 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127 USD | +0.09% | +1.30% | +16.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.49% | 321B | |
+25.61% | 672B | |
+25.87% | 570B | |
-5.24% | 360B | |
+8.28% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
+5.01% | 199B | |
-8.75% | 149B | |
-5.21% | 147B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck - European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent